EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pyxis Oncology's enterprise value is $-13.11 Mil.
Pyxis Oncology's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, Pyxis Oncology's EV-to-Revenue for today is .
The historical rank and industry rank for Pyxis Oncology's EV-to-Revenue or its related term are showing as below:
PYXS'
s EV-to-Revenue Range Over the Past 10 Years
Min: -3.15 Med: 2.18 Max: 8.92
Current: -0.81
During the past 6 years, the highest EV-to-Revenue of Pyxis Oncology was 8.92. The lowest was -3.15. And the median was 2.18.
PYXS's EV-to-Revenue is ranked better than 93.37% of 995
companies
in the Biotechnology industry
Industry Median: 7.6
vs PYXS: -0.81
As of today (2025-06-24), Pyxis Oncology's stock price is $1.21.
Pyxis Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00. Therefore, Pyxis Oncology's PS Ratio for today is .
Pyxis Oncology EV-to-Revenue Historical Data
The historical data trend for Pyxis Oncology's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pyxis Oncology's EV-to-Revenue
For the Biotechnology subindustry, Pyxis Oncology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's EV-to-Revenue falls into.
Pyxis Oncology's current Enterprise Value is $-13.11 Mil.
Pyxis Oncology's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pyxis Oncology's share price for today is $1.21.
Pyxis Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pyxis Oncology EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Pyxis Oncology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PYXS has been successfully added to your 